Approach to the diagnosis and management of lipoprotein disorders

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 2, 2009, Pages 132-140

  Alwaili, Khalid ^a   Alrasadi, Khalid ^a   Awan, Zuhier ^a   Genest, Jacques ^a,b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cardiovascular risk; Cholesterol; Dyslipidemia; Hyperlipidemia; Metabolic syndrome

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESEVELAM; DOCOSAHEXAENOIC ACID; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PHYTOSTEROL; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; LIPOPROTEIN;

ABDOMINAL DISCOMFORT; ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; DIETARY INTAKE; DISEASE CLASSIFICATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DISORDERS OF LIPOPROTEIN METABOLISM; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FAT INTAKE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GLYCEMIC CONTROL; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPOPROTEIN DEFICIENCY; LIVER TOXICITY; METABOLIC SYNDROME X; MONOTHERAPY; MORTALITY; MUSCLE DISEASE; MUSCLE TOXICITY; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL CONTRACEPTION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROPHYLAXIS; PRURITUS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; SMOKING CESSATION; STOMACH IRRITATION; STRESS MANAGEMENT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANIMAL; CLASSIFICATION; METABOLISM;

ANIMALS; ANTILIPEMIC AGENTS; DYSLIPIDEMIAS; GENE THERAPY; HUMANS; LIPOPROTEINS; METABOLIC SYNDROME X;

EID: 66149088876     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328329135a     Document Type: Review

References (43)

1. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110:227-239.
2. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
3. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
4. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444:881-887.
5. World Health Organisation, Human Genetics Programme (1997) Familial Hypercholesterolemia (FH): report of a WHO Consultation, Paris; 3 October 1997; Geneva, Switzerland.
6. Alberti KG, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome? A new worldwide definition. Lancet 2005; 366:1059-1062.
7. Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004; 27:1182-1186.
8. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28:2745-2749.
9. Ruan H, Lodish HF. Regulation of insulin sensitivity by adipose tissue-derived hormones and inflammatory cytokines. Curr Opin Lipidol 2004; 15:297-302.
10. Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27:788-793.
11. Han TS, Williams K, Sattar N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res 2002; 10:923-931.
12. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808.
13. You T, Yang R, Lyles MF, et al. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2005; 288:E741-E747.
14. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1:1575-1579.
15. Kern PA, Di Gregorio GB, Lu T, et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52:1779-1785.
16. Ross R. Atherosclerosis? An inflammatory disease. N Engl J Med 1999; 340:115-126.
17. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:1876-1890.
18. •] uncovering the importance of systemic low-grade inflammation in the initiation and development of atherosclerosis as well as acute CVD events.
19. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
20. Fichtlscherer S, Heeschen C, Zeiher AM. Inflammatory markers and coronary artery disease. Curr Opin Pharmacol 2004; 4:124-131.
21. Hurt-Camejo E, Camejo G, Peilot H, et al. Phospholipase A2 in vascular disease. Circ Res 2001; 89:298-304.
22. Khovidhunkit W, Memon RA, Reinglod KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000; 181 (Suppl 3):S462-S472.
23. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23:1835-1839.
24. Ridker PM, Fonseca FAH, Genest J, et al., and JUPITER Trial Study Group. Baseline characteristics of participants in the JUPITER Trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007; 100:1659-1664.
25. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Eng J Med 2008; 358:2195-2207. A landmark study supporting the concept that hsCRP is a cardiovascular risk marker and may be part of cardiovascular risk stratification.
26. Larosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Eng J Med 2005; 352:1425-1435.
27. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs. usual dose simvastatin for secondary prevention after myocardial infarction - the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445.
28. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy - thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
29. SEARCH Study Collaborative Group, Bowman L, Armitage J, et al. Characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J 2007; 154:815-823.
30. Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006; 113:1406-1414.
31. Baigent C, Keech A, Kearney PM, et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
32. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction?: A meta-regression analysis. J Am Coll Cardiol 2005; 46:1855-1862.
33. Ridker PM, JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108:2292-2297.
34. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303:1201-1204.
35. Genest J. Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Can J Cardiol 2006; 22:863-868.
36. Kastelein JJ, Akdim F, Stroes ES, et al., ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431-1443.
37. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008; 168:1975-1983.
38. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008; 168:1531-1540.
39. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31:1479-1484.
40. Sebestjen M, Keber I, Zegura B, et al. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 2004; 92:1129-1135.
41. Scott R, O'Brien R, Fulcher G, et al., on behalf of the FIELD Study Investigators. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 2009; 32:493-498.
42. Kjekshus J, Apetrei E, Barrios V, et al., CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357:2248-2261.
43. Gissi-Hf Investigators, Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1231-1239. Two recent studies showing that statins may not prevent major CVE in advanced heart failure.